AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05011149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: Pharmacotherapy, when indicated (ie, for severe PDA on echocardiography, irrespective of clinical symptoms, or a moderate PDA on echocardiography with at least moderate clinical illness), will be provided in the form of ibuprofen as first line agent at a standard dosing of 10 mg/kg followed by 2 doses of 5mg/kg every 24 h. The route of administration may be intravenous or enteral, as determined by the treating team.~For treated infants, follow-up echocardiography will be conducted at the end of the 3-day course and second course of treatment will be initiated if they still fulfill study treatment criteria as mentioned above. If any treatment-eligible infant has a contraindication to ibuprofen, use of acetaminophen will be permitted as an alternative agent.
Study NCT06230484 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Invisalign first palatal expander
Description: Most recently, a new design of a removable expander by Align was brought to our attention. In this prospective clinical study, the investigators will compare the patient-reported treatment outcomes and the dental-skeletal treatment effects on palatal dimensions. With this study, the investigators will have a better understanding of this newly developed appliance and its application in early orthodontic treatment.
Study NCT06230484 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rapid maxillary expansion
Description: Malocclusions with narrow upper arches are usually treated in the mixed dentition with a traditional bonded maxillary expander.
Study NCT05249205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REHIT1
Description: This intervention involves a single REHIT exercise session per week. REHIT involves 10 minutes of unloaded cycling on a stationary bike interspersed with two 20-second 'all-out' cycle sprints against a resistance equivalent to 7.5% of body mass.
Study NCT05249205 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REHIT2
Description: This intervention is the same as that for the REHIT1 intervention, but with 2 sessions per week instead of 1.
Study NCT06113003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic
Description: Wheat dextrin fiber
Study NCT06113003 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic packet
Study NCT05305898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Patients from metformin group will receive metformin 3 x 850 mg (after titration period) for 2 years (3 x 500 mg for first 6 weeks) with 6 months follow-up after treatment cessation.
Study NCT04731896 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amniotomy
Description: artificial rupture of the amniotic sac
Study NCT05173805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YL-15293
Description: After enrollment, patients will receive oral YL-15293 twice a day until disease progression, unacceptable adverse events, concurrent diseases prevent further study treatment, the investigator decides to withdraw the patient, the patient withdraws consent, the patient is pregnant, or for administrative reasons. After treatment, the patients will continue to be followed up for 30 days. Patients who permanently stop the study treatment for reasons other than disease progression will be followed up for disease evaluation after treatment until the start of new anti-cancer treatment, withdrawal of consent, loss of follow-up, death or until the sponsor stops the study, whichever comes first.
Study NCT04091191 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Meta19.01
Description: A specialized nutraceutical containing plant extracts, vitamins and fish oil
Study NCT04091191 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meta19.01
Description: A specialized nutraceutical containing plant extracts, vitamins and fish oil
Study NCT05106686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Aureobasidium pullulans produced β-glucan group
Description: Aureobasidium pullulans produced β-glucan 1,000 mg/day for 12 weeks
Study NCT05106686 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo group
Description: Placebo 300 mg/day for 12 weeks
Study NCT06062381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Abdominal Massage
Description: The intervention period will be 3 days for intervention group. These patients will receive 20 minutes of abdominal massage twice a day, and the interval between two massages will be 2 hours. The outcome variable variable gastric residual volume will be measured every day, before the intervention and 1 hour after the second massage. the GRV will be measured in ml (via feeding syringe) and marked on checklist.~The abdominal massage technique will consist of five steps based on tensegrity principle.~The lubricant gel will be used to facilitate the massaging. The patient's position will be supine while going through abdominal massage. The angle between the bed and the patient's head will be 30 to 45 degrees, and the patient's legs will be placed on a pillow. This condition will help to relax the abdominal muscles.
Study NCT05973708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clamshell Exercise
Description: Clamshell Exercise: The clamshell exercise keeps the hips moving, it strengthens both the gluteus medius AND gluteus maximus. The gluteus medius is the main abductor (movement away from the midline of the body) and external rotator of the hip.
Study NCT05973708 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Frog pump exercise
Description: Frog pump exercise: The frog hip thrust mainly targets the gluteal muscles responsible for thigh extension and abduction. The exercise also works the hamstrings on the back of the thighs which helps in hip extension.
Study NCT05266846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab injection
Description: Pembrolizumab 20mg ivgtt once every 21day Platium based Chemotherapy ivgtt once every 21day Bevacizumab 15mg/kg ivgtt once every 21day
Study NCT05190159 — intervention group
Intervention type: DEVICE
Intervention: Monster Screw System
Description: Subjects who have undergone a foot and/or ankle procedure involving the index device
Study NCT05433493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive stimulation
Description: The intervention program will have 24 sessions (base scheme of 4 series of 6 sessions), lasting approximately 45 min and will be developed according to the following structure: - welcoming (greeting to the participant) (5 min); - orientation to reality (10 min); - main cognitive stimulation activity (25 min); - return to calm and evaluation of the session (5 min).~The CS sessions will have an individual format and will be conducted by a professional with experience in CS and previously trained in this intervention. The intervention sessions will include several activities based on the CS principles, with evidence suggesting positive participant effects. The CS sessions will be carried out using material, developed by the principal investigator, in digital format (power point presentations). There will be no repetition of activities, and throughout the base CS program, the degree of difficulty of the exercises will be adjusted based on the dementia stage of the participant.
Study NCT04376515 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HOPE intervention
Description: Online peer support community of peers trained in behavior change science
Study NCT05007392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dotinurad
Description: Dotinurad oral tablets.
Study NCT05007392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat
Description: Febuxostat oral tablets.
Study NCT05007392 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dotinurad Matched Placebo
Description: Dotinurad matched placebo oral tablets.
Study NCT05007392 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Febuxostat Matched Placebo
Description: Febuxostat matched placebo oral tablets.
Study NCT05924516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adhera® Fatigue Digital Program
Description: The Adhera® Fatigue Digital Program is delivered via a mobile application and includes personalized educational and interactive content. The program is designed to support the wellbeing of people living with type 2 diabetes, including self-management education and support. This also includes a focus on diabetes-related fatigue.
Study NCT05129761 — intervention group
Intervention type: DRUG
Intervention: Syrup Hydryllin
Description: ( Syrup Hydryllin \& Hydryllin Sugar-Free (Diphenhydramine, Ammonium Chloride, Menthol, Aminophylline) and Syrup Hydryllin DM (Dextromethorphan \& Diphenhydramine)
Study NCT06292377 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ECG
Description: An electrocardiogram (ECG) is a simple, non-invasive test that records the electrical activity of the heart.
Study NCT06292377 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Transthoracic echography (TTE)
Description: A transthoracic echocardiogram (TTE) is a test that uses ultrasound (sound waves) to create images of the heart.
Study NCT06292377 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling will include: complete blood count, serum creatinine and electrolytes, liver enzymes, fast lipid profile, glucose, HbA1C, thyroid-stimulating hormone (TSH), CRP, iron status, cardiac troponin (cTnT), N-terminal pro-brain natriuretic peptide (NT-proBNP).
Study NCT05137691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adapted NHS weight management 1:1 programme
Description: Adapted NHS 1:1 weight management programme with a low carbohydrate dietary focus, incorporating enhanced behaviour change via telehealth, step count and pedometer
Study NCT05137691 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NHS 1:1 weight management programme
Description: NHS 1:1 weight management programme
Study NCT05043181 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low Density Lipoprotein Receptor mRNA Exosomes
Description: The study consists of two phases: dose escalation phase and extension phase. Dose escalation phase：For the intervention of low-density lipoprotein receptor mRNA (LDLR mRNA) exosomes. A total of six dose groups are planned, with single dose of 0.044 mg/kg, 0.088 mg/kg, 0.145 mg/kg, 0.220 mg/kg, 0.295 mg/kg and 0.394 mg/kg, respectively. About 3 subjects are enrolled in each dose group. In the 0.044 mg/kg group, the second and third subjects are required to start exosome infusion treatment after the treatment of the previous subjects, and the other dose groups are not required to do this. There are three treatments in total, and the interval between each exosome treatment is 7±1 d.~Extension phase: About 12 subjects are further enrolled. The subjects will receive 3 intravenous/peritoneal infusion treatment of LDLR mRNA exosomes once a week for three weeks, whose single dose is determined in the dose escalation phase.
Study NCT04342091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SOL Nova Device
Description: A SOL Nova Device (brand) is tattoo machine will be used to stimulate hair regrowth.
Study NCT00716339 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: motivation
Study NCT05034276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MORE-VR
Description: Mindfulness-Oriented Recovery Enhancement therapy delivered over virtual reality.
Study NCT05303376 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBIO123
Description: 5 or 10 mg
Study NCT05303376 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo
Study NCT05134636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Text triage
Description: The e-triage will consist of 16 questions, modified from the validated NCI Pro-CTCAETM, which will be sent to patients via WaytoHealth©'s two-way texting system 96 hours prior to their scheduled immunotherapy infusion. Questions will pertain to common or emergent immune related adverse events as defined by the NCCN guidelines and two senior disease experts. Patients will be prompted via text to measure the presence and severity of symptoms over the week prior. A final question will be included to capture any additional symptoms patients wish to disclose.
Study NCT06443749 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: appendectomy
Description: the appendiceal stump will be closed with a polyper homologous clip or with an intracorporial node
Study NCT05848973 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Diet
Description: The targeted study participants will be given advice about healthy dietary intakes. This will entail promotion of foods rich in vegetables/fruits and wholegrain/fibre, fish, olive oil; moderate in lean red meat and low-fat diary products). To be concrete, the study investigators will target energy (E%) from macronutrients as follows: 42 E% total fat (≥ 22 E% from monounsaturated fatty acids, 10 E% from polyunsaturated fatty acids and \<10 E% saturated fatty acids), 35 E% carbohydrate, 15 E% protein and ≤ E 5% alcohol. Importantly, this will meet all Recommended Dietary Intake requirements for adults.
Study NCT05848973 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-based cognitive therapy (MBCT)
Description: MBCT is a skills-based intervention comprising a structured 8-week group intervention program to be delivered in groups of study participants, with an all-day practice session around week six and regular reunion sessions thereafter.
Study NCT04777474 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Enhanced contact endoscopy
Description: The study subjects will undergo enhanced contact endoscopy - studied imaging technique
Study NCT04777474 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Narrow band imaging
Description: The study subjects will undergo narrow band imaging - comparator procedure
Study NCT04777474 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: IMAGE1S imaging
Description: The study subjects will undergo IMAGE1S imaging - comparator procedure
Study NCT05989295 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: probiotic LRa05
Description: treatment about 12 weeks
Study NCT05989295 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: probiotic LRa05
Description: treatment about 12 weeks
Study NCT05465434 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zinc Supplement
Description: Zinc sulphate 50 mg
Study NCT05145400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab
Description: Pharmaceutical form: Solution for infusion Route of administration: Intravenous Isatuximab :10 mg/kg intravenous will be administered in cycle 1-24.
Study NCT05145400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Pharmaceutical form: Capsule for oral use, Route of administration: Oral Lenalidomide capsule will be given oral, the dose will be adjusted according to glomerular filtration rate (GFR): 15 mg daily if GFR > 60 mL/min, 5 mg daily if GFR 30-60 mL/min, 2.5 mg daily if GFR \< 30 mL/min. Note that dialysis-dependence comprises an exclusion criterion for this study.~Lenalidomide will be continued until disease progression, excessive toxicity or death.
Study NCT05145400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form: Tablet for oral use, Route of administration: Oral Dexamethasone tablet will be given oral: 20 mg given on days 1, 8, 15 and 22 of cycles 1-8. Administration may continue beyond cycle 8, if needed, for the prevention of infusion reactions.
Study NCT05031429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time Limited Eating
Description: Includes an 8-hour feed/16-hour fast for 7 days per week, with consumption of all of calories in the afternoon/evening. Can consume non-caloric beverages (water, tea, coffee) during the fasting period. No caloric restriction will be used.
Study NCT06204601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education According to Meleis' Transitional Theory to Patients With Pacemaker
Description: Patients in the experimental group will be trained according to Meleis's Transition Theory.
Study NCT05979870 — intervention group
Intervention type: PROCEDURE
Intervention: Valvuloplasty,
Description: Choice of type of intervention decided on a multidisciplinary conference
Study NCT06394817 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT05902780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal Bupivacaine injection
Description: - Group B (n =25): In this group, and after induction of general anesthesia, pediatric patients will receive a caudal injection of bupivacaine 0.125 % in a dose of 1ml/kg.
Study NCT05902780 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caudal Dexmedetomidine Injection
Description: - Group D (n =25): In this group, and after induction of general anesthesia, pediatric patients will receive a caudal injection of dexmedetomidine in a dose of 1.5 mcg/kg.
Study NCT05934110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMP16-120/40
Description: EMP16 is supplied as oral MR capsules with the strength of 60 mg orlistat/20 mg acarbose.~Dosage:~week 1-2: 60 mg orlistat/20 mg acarbose (1 capsule per day), week 3-4: 60 mg orlistat/20 mg acarbose (1 capsule TID), week 5-26: 60 mg orlistat/20 mg acarbose (2 capsules TID).
Study NCT05165836 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Erector Spinae Plane block without Dexmedetomidine group
Description: Block will be performed with an ultrasound machine (Philips CX50 Extreme edition). A 2-5 MH2 curved probe will be positioned transversely to visualize the lateral tip of thoracic vertebrae2 transverse Process. Before surgery with patients in sitting position, the transducer will be positioned longitudinally 3 cm lateral to the thoracic vertebrae2 spinous process. The trapezius, rhomboid major, and erector spinae muscles will be revealed superficial to the shadow of the hyperechoic transverse process. Then, 3ml lidocaine 2% will be used to anesthetize the skin. Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 19 ml of bupivacaine 0.25% + 1 mL saline will be injected. The needle tip's placement will be confirmed by observable fluid spread lifting the erector spinae muscle away from the transverse process's bony shadow.
Study NCT05165836 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane block with Dexmedetomidine group
Description: Block will be performed with an ultrasound machine (Philips CX50 Extreme edition). A 2-5 MH2 curved probe will be positioned transversely to visualize the lateral tip of thoracic vertebrae2 transverse Process. Before surgery with patients in sitting position, the transducer will be positioned longitudinally 3 cm lateral to the thoracic vertebrae2 spinous process. The trapezius, rhomboid major, and erector spinae muscles will be revealed superficial to the shadow of the hyperechoic transverse process. Then, 3ml lidocaine 2% will be used to anesthetize the skin. Using a 20-gauge block needle put in-plane in a cephalad-to-caudad orientation to position the tip into the fascial plane on the deep (anterior) side of the erector spinae muscle, 19 ml of bupivacaine 0.25% + 1 mL dexmedetomidine 0.5 µg/kg will be injected. The needle tip's placement will be confirmed by observable fluid spread lifting the erector spinae muscle away from the transverse process's bony shadow.
Study NCT05397275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: progressive muscle relaxation+breathe exercises
Description: progressive muscle relaxation+breathe exercises
Study NCT05397275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathe exercises
Description: breathe exercises
Study NCT05934110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MR orlistat 120 mg
Description: MR orlistat 120 mg is the same as EMP16-120/40 but without the acarbose component in matching oral capsules.~Dosage:. week 1-2: 60 mg MR orlistat (1 capsule per day), week 3-4: 60 mg MR orlistat (1 capsule TID), week 5-26: 60 mg MR orlistat (2 capsules TID).
Study NCT05934110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional orlistat 120 mg,
Description: Orlistat in its conventional form will be Alli® 60 mg during week 1 to 4 and Xenical® 120 mg from week 5 and onwards in matching oral capsules.~Dosage:~week 1-2: 60 mg conventional orlistat (1 capsule per day), week 3-4: 60 mg conventional orlistat (1 capsule TID), week 5-26: 120 mg conventional orlistat plus placebo (1 capsule of each TID).
Study NCT05934110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMP16-60/20
Description: Dosage:~week 1-2: 60 mg orlistat/20 mg acarbose (1 capsule per day), week 3-4: 60 mg orlistat/20 mg acarbose (1 capsule TID), week 5-26: 60 mg orlistat/20 mg acarbose plus placebo (1 capsule of each TID)
Study NCT05934110 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Dosage:~week 1-2: Placebo (1 capsule per day), week 3-4: Placebo (1 capsule TID), week 5-26: Placebo (2 capsules TID)
Study NCT05934110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Dosage:~week 1-2: Placebo (1 capsule per day), week 3-4: Placebo (1 capsule TID), week 5-26: Placebo (2 capsules TID)
Study NCT05934110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dosage:~week 1-2: Placebo (1 capsule per day), week 3-4: Placebo (1 capsule TID), week 5-26: Placebo (2 capsules TID)